You want energy back and a full workday that does not fall off a cliff by 3 p.m. You also want to keep the door open to having children on your own timeline. Those two goals do not have to compete, but they do require a real conversation about mechanism, not marketing.

This article is educational and is not medical advice. Whether any medication is appropriate for you is a decision made with an independent, licensed provider based on your labs, history, and goals.

Why fertility is even part of this conversation

Testosterone is regulated by a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. The brain releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which tell the testes to make testosterone and to support sperm production [1]. Intratesticular testosterone, the level inside the testes, needs to be far higher than blood levels for normal sperm production [2].

Here is the part that matters for a founder or an athlete planning a family: when you add testosterone from the outside, the brain senses plenty of testosterone and dials down LH and FSH. That drop can suppress the testes' own production and, in many men, sharply reduce sperm output [1][2]. This is the mechanism behind the fertility concern you have read about, and it is real physiology, not a rumor.

Path A: Exogenous testosterone (often called TRT)

Exogenous testosterone replaces the hormone directly. Because it works from the outside, it can raise blood testosterone regardless of what your own axis is doing. But that same outside-in approach is what suppresses LH and FSH, and with them, sperm production in many men [1][3].

Professional guidance reflects this. The Endocrine Society's clinical practice guideline advises against prescribing testosterone for men who are planning fertility in the near term, precisely because of this suppression [3]. The FDA-approved labeling for testosterone products also notes that testosterone can suppress spermatogenesis [4].

Reversibility is nuanced. For many men sperm production returns after stopping, but the timeline varies widely and recovery is not guaranteed for everyone [2]. If your family timeline is uncertain, that variability is the crux of the trade-off.

Path B: Enclomiphene (a selective estrogen receptor modulator)

Enclomiphene takes the opposite approach. It works inside-out. Rather than supplying testosterone, it blocks estrogen receptors at the hypothalamus and pituitary, which the brain interprets as a signal to release more LH and FSH [5]. Those signals then stimulate the testes to produce more of their own testosterone, keeping the axis running rather than shutting it down [5][6].

Because enclomiphene relies on your own signaling, it generally preserves or supports the LH and FSH activity that matters for sperm production, which is why it is discussed in the context of men who want to raise testosterone while keeping fertility on the table [5][6]. It is important to be precise here: this is a mechanistic distinction, not a promise about any individual's fertility or outcome.

A note on regulatory status: enclomiphene is not an FDA-approved standalone product for this use, and it is commonly prescribed as a compounded medication. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

The trade-offs, side by side

  • Mechanism: Exogenous testosterone works outside-in and can suppress the HPG axis; enclomiphene works inside-out and stimulates it [1][5].
  • Fertility signal: Outside testosterone tends to lower LH and FSH; enclomiphene tends to raise them [3][5].
  • Monitoring: Both require lab follow-up. A provider may track total and free testosterone, LH, FSH, estradiol, hematocrit (red blood cell concentration), and a lipid panel, adjusting based on your response [3][7].
  • Reversibility: Enclomiphene's effect is generally tied to ongoing use and axis stimulation; recovery of sperm production after stopping exogenous testosterone varies by individual and can take time [2].
Two mechanisms, opposite directions
Outside-inExogenous testosteroneCan suppress LH and FSH
Inside-outEnclomipheneStimulates LH and FSH
Lab-monitoredBoth pathsFollow-up testing required

Source: [1] Physiology, Gonadotropin-Releasing Hormone (HPG axis) - StatPearls, NCBI Bookshelf, [3] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [5] Enclomiphene citrate and its pharmacology - NIH/PMC

What an independent provider actually asks

The Velri clinical review process connects you with an independent, licensed provider. Matching a tool to an uncertain timeline starts with questions, not a prescription. Expect a provider to explore:

  • How firm is your family timeline? "Someday" and "within a year" point toward different conversations about reversibility and monitoring [3].
  • What do your labs actually show? A single "low normal" reading is not the whole picture. Guidelines emphasize confirming low testosterone on more than one morning measurement before considering therapy, alongside symptoms [3].
  • Are LH and FSH high, low, or normal? These help distinguish where in the axis the issue sits, which shapes options [1][3].
  • What are your baseline hematocrit, estradiol, and lipids? These inform safety monitoring over time [3][7].
  • What are your priorities if they conflict? Naming the fertility priority out loud is exactly the kind of goal a provider should treat as central, not incidental.

A prescription is never guaranteed. It is a clinical decision made by an independent, licensed provider based on your specific situation.

Confirming low testosterone before therapy
Single reading (not sufficient alone) ≤1Repeat to confirm ≤2Guideline emphasis: confirmed low ≤3

morning measurements · marker = Guideline approach

Source: [3] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline

A word on doing this supervised

Gray-market hormones with no labs and no oversight remove the two things that make this safe: baseline data and follow-up. The whole point of a supervised path is that someone is watching the numbers that can drift, like hematocrit, and adjusting accordingly, while keeping your stated goals, including fertility, in view [3][7]. Being an athlete or a founder with optimization goals is not a reason to be dismissed; it is a reason to insist on real testing and real oversight.

How a supervised path is typically sequenced
1Baseline labsTestosterone, LH, FSH, estradiol, hematocrit, lipids
2Independent provider visitSymptoms, history, and goals reviewed
3DecisionClinical judgment, never guaranteed
4Follow-up monitoringRecheck labs, adjust as needed

Source: [3] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [7] Adverse effects of testosterone therapy: monitoring hematocrit and lipids - NIH/PMC

Where Velri fits

Velri is a technology and coordination company. It does not provide medical care. Velri helps coordinate the pieces: lab work so a decision starts with data, a visit with an independent, physician-led Provider Group, and, if a provider prescribes something, fulfillment through an independent, licensed pharmacy. Care is provided by independent Provider Groups, and medications are dispensed by independent pharmacies.

Coverage starts in Nevada, with more states rolling out over time. Whether any specific medication, including compounded enclomiphene, is appropriate or available depends on your labs, your state, and the judgment of an independent, licensed provider.

This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Talk with a licensed provider about your individual situation.